Circassia pockets $21.8M in second VC round

Goldman Sachs and Invesco Perpetual have signed on as new investors in Circassia, a UK biotech exploring ways to control immune responses. They helped put up $21.8 million in Circassia's second round of venture capital. Circassia's lead products target allergies using its T-cell epitope desensitization technology, which was originally developed at Imperial College London.

"We have made good progress advancing our anti-allergy products during the last year, and successfully completing this funding, particularly in the current challenging market conditions, is a strong vote of confidence from a syndicate of world-class investors," says Steve Harris, Circassia's CEO.

- check out the release for more

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.